Patents by Inventor Mark G. Erlander

Mark G. Erlander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits useful for detecting autoantibody to glutamic acid decarboxylase
    Patent number: 5846740
    Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
    Type: Grant
    Filed: September 22, 1995
    Date of Patent: December 8, 1998
    Assignee: The Regents of The University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Method for simulataneous identification of differentially expresed mRNAS and measurement of relative concentrations
    Patent number: 5807680
    Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3'-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3'-primer whose sequence is derived from the vector and a set of 5'-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.
    Type: Grant
    Filed: October 17, 1995
    Date of Patent: September 15, 1998
    Assignee: The Scripps Research Institute
    Inventors: J. Gregor Sutcliffe, Mark G. Erlander
  • Cloned glutamic acid decarboxylase nucleic acids
    Patent number: 5705626
    Abstract: The invention is directed to isolated polypeptides useful in ameliorating autoimmune disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 6, 1998
    Assignee: The Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Peptides derived from glutamic acid decarboxylase
    Patent number: 5674978
    Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: October 7, 1997
    Assignee: The Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman, Michael J. Clare-Salzler
  • Cloned glutamic acid decarboxylase peptides
    Patent number: 5475086
    Abstract: Isolated polypeptides useful in ameliorating autoimmune disease.
    Type: Grant
    Filed: October 13, 1993
    Date of Patent: December 12, 1995
    Assignee: The Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman, Michael J. Clare-Salzler
  • Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
    Patent number: 5459037
    Abstract: An improved method for the simultaneous sequence-specific identification of mRNAs in a mRNA population allows the visualization of nearly every mRNA expressed by a tissue as a distinct band on a gel whose intensity corresponds roughly to the concentration of the mRNA. In general, the method comprises the formation of cDNA using anchor primers to fix a 3'-endpoint, producing cloned inserts from the cDNA in a vector containing a bacteriophage-specific promoter for subsequent RNA synthesis, generating linearized fragments of the cloned inserts, preparing cRNA, transcribing cDNA from the cRNA using a set of primers, and performing PCR using a 3'-primer whose sequence is derived from the vector and a set of 5'-primers that is derived from the primers used for transcription of cDNA from cRNA. The method can identify changes in expression of mRNA associated with the administration of drugs or with physiological or pathological conditions.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: October 17, 1995
    Assignee: The Scripps Research Institute
    Inventors: J. Gregor Sutcliffe, Mark G. Erlander